

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA liraglutide for managing overweight and obesity

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

The committee recognised the following equality and equity issue during the appraisal discussion:

- There is variability in access to tier 3 services across England, which is the most appropriate setting in which Liraglutide would be administered. The committee recognises that there are equity of access issues regarding tier 3 services in England.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other quality issues raise by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No adverse impact on people with disability.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No recommendations the committee need to make.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes. Section 3.1, 3.2 and 3.3.

## Final appraisal determination

(when an ACD issued)

|  |
|--|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?   |
| The committee noted that black, Asian and other ethnic minority groups are at risk of the consequences of obesity at a lower BMI than white people. The recommendation considers this and includes a recommendation to note this and a lower BMI threshold for BAME ethnic groups.                   |
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?     |
| N/A  |
| 3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?  |
| No adverse impact on people with disability.   |
| 4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality? |
| N/A  |

|   |
|---|
| 5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| Yes. Sections 3.1, 3.2 and 3.3.   |

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 23 October 2020